A non membrane-targeted human soluble CD59 attenuates choroidal neovascularization in a model of age related macular degeneration

PLoS ONE

Volumn 6, Issue 4, 2011, Pages

  Cashman, Siobhan M ^a   Ramo, Kasmir ^a   Kumar Singh, Rajendra ^a  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; CD59 ANTIGEN; PARVOVIRUS VECTOR; COMPLEMENT MEMBRANE ATTACK COMPLEX;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DISEASE MODEL; DRUG TARGETING; HUMAN; HUMAN CELL; LASER; MEMBRANE FORMATION; MOUSE; NONHUMAN; RETINA MACULA AGE RELATED DEGENERATION; SUBRETINAL NEOVASCULARIZATION; TRANSGENE; VIRAL GENE DELIVERY SYSTEM; ADENO ASSOCIATED VIRUS; ADENOVIRUS; ANIMAL; CELL LINE; CHEMISTRY; GENE THERAPY; GENETICS; METABOLISM; METHODOLOGY; PATHOPHYSIOLOGY; RETINA; RETINA MACULA DEGENERATION; SOLUBILITY;

ADENO-ASSOCIATED VIRUS; ADENOVIRIDAE; ANIMALIA; MURINAE; MUS;

ADENOVIRIDAE; ANIMALS; ANTIGENS, CD59; CELL LINE; CHOROIDAL NEOVASCULARIZATION; COMPLEMENT MEMBRANE ATTACK COMPLEX; DEPENDOVIRUS; DISEASE MODELS, ANIMAL; GENE THERAPY; HUMANS; LASERS; MACULAR DEGENERATION; MICE; RETINA; SOLUBILITY;

EID: 79955721853     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0019078     Document Type: Article

References (41)

1. de Jong PT, (2006) Age-related macular degeneration. N Engl J Med 355: 1474-1485.
2. Michels S, Schmidt-Erfurth U, Rosenfeld PJ, (2006) Promising new treatments for neovascular age-related macular degeneration. Expert Opin Investig Drugs 15: 779-793.
3. Anderson DH, Radeke MJ, Gallo NB, Chapin EA, Johnson PT, et al. (2010) The pivotal role of the complement system in aging and age-related macular degeneration: hypothesis re-visited. Prog Retin Eye Res 29: 95-112.
4. Walport MJ, (2001) Complement. Second of two parts. N Engl J Med 344: 1140-1144.
5. Walport MJ, (2001) Complement. First of two parts. N Engl J Med 344: 1058-1066.
6. Anderson DH, Mullins RF, Hageman GS, Johnson LV, (2002) A role for local inflammation in the formation of drusen in the aging eye. Am J Ophthalmol 134: 411-431.
7. Hageman GS, Anderson DH, Johnson LV, Hancox LS, Taiber AJ, et al. (2005) A common haplotype in the complement regulatory gene factor H (HF1/CFH) predisposes individuals to age-related macular degeneration. Proc Natl Acad Sci U S A 102: 7227-7232.
8. Benzaquen LR, Nicholson-Weller A, Halperin JA, (1994) Terminal complement proteins C5b-9 release basic fibroblast growth factor and platelet-derived growth factor from endothelial cells. J Exp Med 179: 985-992.
9. Halperin JA, Taratuska A, Nicholson-Weller A, (1993) Terminal complement complex C5b-9 stimulates mitogenesis in 3T3 cells. J Clin Invest 91: 1974-1978.
10. Bora NS, Kaliappan S, Jha P, Xu Q, Sivasankar B, et al. (2007) CD59, a complement regulatory protein, controls choroidal neovascularization in a mouse model of wet-type age-related macular degeneration. J Immunol 178: 1783-1790.
11. Meri S, Morgan BP, Davies A, Daniels RH, Olavesen MG, et al. (1990) Human protectin (CD59), an 18,000-20,000 MW complement lysis restricting factor, inhibits C5b-8 catalysed insertion of C9 into lipid bilayers. Immunology 71: 1-9.
12. Davies A, Simmons DL, Hale G, Harrison RA, Tighe H, et al. (1989) CD59, an LY-6-like protein expressed in human lymphoid cells, regulates the action of the complement membrane attack complex on homologous cells. J Exp Med 170: 637-654.
13. Rollins SA, Sims PJ, (1990) The complement-inhibitory activity of CD59 resides in its capacity to block incorporation of C9 into membrane C5b-9. J Immunol 144: 3478-3483.
14. Lehto T, Meri S, (1993) Interactions of soluble CD59 with the terminal complement complexes. CD59 and C9 compete for a nascent epitope on C8. J Immunol 151: 4941-4949.
15. Sugita Y, Ito K, Shiozuka K, Suzuki H, Gushima H, et al. (1994) Recombinant soluble CD59 inhibits reactive haemolysis with complement. Immunology 82: 34-41.
16. Vakeva A, Jauhiainen M, Ehnholm C, Lehto T, Meri S, (1994) High-density lipoproteins can act as carriers of glycophosphoinositol lipid-anchored CD59 in human plasma. Immunology 82: 28-33.
17. Fraser DA, Harris CL, Williams AS, Mizuno M, Gallagher S, et al. (2003) Generation of a recombinant, membrane-targeted form of the complement regulator CD59: activity in vitro and in vivo. J Biol Chem 278: 48921-48927.
18. Mizuno M, Nishikawa K, Spiller OB, Morgan BP, Okada N, et al. (2001) Membrane complement regulators protect against the development of type II collagen-induced arthritis in rats. Arthritis Rheum 44: 2425-2434.
19. Bora NS, Jha P, Lyzogubov VV, Kaliappan S, Liu J, et al. (2010) Recombinant membrane-targeted form of CD59 inhibits the growth of choroidal neovascular complex in mice. J Biol Chem 285: 33826-33833.
20. Ramo K, Cashman SM, Kumar-Singh R, (2008) Evaluation of adenovirus-delivered human CD59 as a potential therapy for AMD in a model of human membrane attack complex formation on murine RPE. Invest Ophthalmol Vis Sci 49: 4126-4136.
21. Appledorn DM, McBride A, Seregin S, Scott JM, Schuldt N, et al. (2008) Complex interactions with several arms of the complement system dictate innate and humoral immunity to adenoviral vectors. Gene Ther 15: 1606-1617.
22. Jiang H, Wang Z, Serra D, Frank MM, Amalfitano A, (2004) Recombinant adenovirus vectors activate the alternative complement pathway, leading to the binding of human complement protein C3 independent of anti-ad antibodies. Mol Ther 10: 1140-1142.
23. Maclachlan TK, Lukason M, Collins M, Munger R, Isenberger E, et al. (2011) Preclinical Safety Evaluation of AAV2-sFLT01- A Gene Therapy for Age-related Macular Degeneration. Mol Ther 19 (2): 326-34.
24. Ricklin D, Lambris JD, (2007) Complement-targeted therapeutics. Nat Biotechnol 25: 1265-1275.
25. Fijen CA, Kuijper EJ, te Bulte MT, Daha MR, Dankert J, (1999) Assessment of complement deficiency in patients with meningococcal disease in The Netherlands. Clin Infect Dis 28: 98-105.
26. Fijen CA, Kuijper EJ, Dankert J, Daha MR, Caugant DA, (1998) Characterization of Neisseria meningitidis strains causing disease in complement-deficient and complement-sufficient patients. J Clin Microbiol 36: 2342-2345.
27. Homann C, Varming K, Hogasen K, Mollnes TE, Graudal N, et al. (1997) Acquired C3 deficiency in patients with alcoholic cirrhosis predisposes to infection and increased mortality. Gut 40: 544-549.
28. Ricklin D, Hajishengallis G, Yang K, Lambris JD, (2010) Complement: a key system for immune surveillance and homeostasis. Nat Immunol 11: 785-797.
29. Rosen AM, Stevens B, (2010) The role of the classical complement cascade in synapse loss during development and glaucoma. Adv Exp Med Biol 703: 75-93.
30. Gragoudas ES, Adamis AP, Cunningham ET Jr, Feinsod M, Guyer DR, (2004) Pegaptanib for neovascular age-related macular degeneration. N Engl J Med 351: 2805-2816.
31. Kim IH, Jozkowicz A, Piedra PA, Oka K, Chan L, (2001) Lifetime correction of genetic deficiency in mice with a single injection of helper-dependent adenoviral vector. Proc Natl Acad Sci U S A 98: 13282-13287.
32. Colella P, Cotugno G, Auricchio A, (2009) Ocular gene therapy: current progress and future prospects. Trends Mol Med 15: 23-31.
33. Jiang H, Pierce GF, Ozelo MC, de Paula EV, Vargas JA, et al. (2006) Evidence of multiyear factor IX expression by AAV-mediated gene transfer to skeletal muscle in an individual with severe hemophilia B. Mol Ther 14: 452-455.
34. Cashman SM, Bowman L, Christofferson J, Kumar-Singh R, (2006) Inhibition of choroidal neovascularization by adenovirus-mediated delivery of short hairpin RNAs targeting VEGF as a potential therapy for AMD. Invest Ophthalmol Vis Sci 47: 3496-3504.
35. Cashman SM, McCullough L, Kumar-Singh R, (2007) Improved Retinal Transduction In Vivo and Photoreceptor-specific Transgene Expression Using Adenovirus Vectors With Modified Penton Base. Mol Ther 15: 1640-1646.
36. Campochiaro PA, Dong Nguyen Q, Mahmood Shah S, Klein ML, Holz E, et al. (2006) Adenoviral Vector-Delivered Pigment Epithelium-Derived Factor for Neovascular Age-Related Macular Degeneration: Results of a Phase I Clinical Trial. Hum Gene Ther 17: 167-176.
37. Chevez-Barrios P, Chintagumpala M, Mieler W, Paysse E, Boniuk M, et al. (2005) Response of retinoblastoma with vitreous tumor seeding to adenovirus-mediated delivery of thymidine kinase followed by ganciclovir. J Clin Oncol 23: 7927-7935.
38. Ildefonso CJ, Kong L, Leen A, Chai SJ, Petrochelli V, et al. Absence of systemic immune response to adenovectors after intraocular administration to children with retinoblastoma. Mol Ther 18: 1885-1890.
39. Sohn JH, Kaplan HJ, Suk HJ, Bora PS, Bora NS, (2000) Complement regulatory activity of normal human intraocular fluid is mediated by MCP, DAF, and CD59. Invest Ophthalmol Vis Sci 41: 4195-4202.
40. Lukason M, Dufresne E, Rubin H, Pechan P, Li Q, et al. (2011) Inhibition of Choroidal Neovascularization in a Nonhuman Primate Model by Intravitreal Administration of an AAV2 Vector Expressing a Novel Anti-VEGF Molecule. Mol Ther 19 (2): 260-5.
41. Fallaux FJ, Kranenburg O, Cramer SJ, Houweling A, Van Ormondt H, et al. (1996) Characterization of 911: a new helper cell line for the titration and propagation of early region 1-deleted adenoviral vectors. HumGene Ther 7: 215-222.